The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Impact of dopamine transporter SPECT using 123I‐Ioflupane on diagnosis and management of patients with clinically uncertain parkinsonian syndromes
Abstract
Imaging with 123 I‐Ioflupane single‐photon emission computed tomography (SPECT) is a marker of nigrostriatal neuronal integrity, allowing differentiation of parkinsonism with loss of dopaminergic terminals (presynaptic Parkinson syndrome [PS]) from parkinsonism without nigrostriatal degeneration. This study assessed SPECT imaging in 118 patients with clinically uncertain parkinsonian syndromes (CUPS). In 36% of patients with presynaptic PS and 54% with nonpresynaptic PS, imaging results were not consistent with the initial diagnosis. After imaging, diagnosis was changed in 52% of patients. All patients with a final diagnosis of presynaptic PS had an abnormal image, whereas 94% of patients with nonpresynaptic PS had a normal scan. Imaging increased confidence in diagnosis, leading to changes in clinical management in 72% of patients. Consequently, visual assessment of 123 I‐Ioflupane SPECT may have a significant impact on the clinical management of CUPS patients. © 2004 Movement Disorder Society
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hughes, A. J., Daniel, S. E., Kilford, L., & Lees, A. J. (1992) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.55.3.181 · Cited by 10,378
Improved accuracy of clinical diagnosis of Lewy body Parkinson’s disease
Hughes, A. J., Daniel, S. E., & Lees, A. J. (2001) · Neurology · doi:10.1212/wnl.57.8.1497 · Cited by 807
Benamer, H. T. S., Patterson, J., Grosset, D. G., Booij, J., de Bruin, K., van Royen, E., Speelman, J. D., Horstink, M. H. I. M., Sips, H. J. W. A., Dierckx, R. A., et al. (2000) · Movement Disorders · doi:10.1002/1531-8257(200005)15:3<503::aid-mds1013>3.0.co;2-v · Cited by 707
Accuracy of Clinical Diagnosis in Parkinsonism — A Prospective Study
Rajput, A. H., Rozdilsky, B., & Rajput, A. (1991) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100031814 · Cited by 596
Cohen, O., Pullman, S., Jurewicz, E., Watner, D., & Louis, E. D. (2003) · Archives of Neurology · doi:10.1001/archneur.60.3.405 · Cited by 298
Accuracy of diagnosis in patients with presumed Parkinson's disease
Meara, J. (1999) · Age and Ageing · doi:10.1093/ageing/28.2.99 · Cited by 265
Booij, J., Speelman, J. D., Horstink, M. W. I. M., & Wolters, E. C. (2001) · European Journal of Nuclear Medicine · doi:10.1007/s002590000460 · Cited by 264
Kaufman, M. J., & Madras, B. K. (1991) · Synapse · doi:10.1002/syn.890090107 · Cited by 236
Isolated tremor and disruption of the nigrostriatal dopaminergic system: An 18 F‐dopa PET study
Brooks, D. J., Playford, E. D., Ibanez, V., Sawle, G. V., Thompson, P. D., Findley, L. J., & Marsden, C. D. (1992) · Neurology · doi:10.1212/wnl.42.8.1554 · Cited by 232
The Evolution of Diagnosis in Early Parkinson Disease
Jankovic, J. (2000) · Archives of Neurology · doi:10.1001/archneur.57.3.369 · Cited by 229
Fortnightly Review: Parkinsonism—recognition and differential diagnosis
Quinn, N. (1995) · BMJ · doi:10.1136/bmj.310.6977.447 · Cited by 186
Larsen, J. P., Dupont, E., & Tandberg, E. (2009) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1994.tb01674.x · Cited by 176
Neumeyer, J. L., Campbell, A., Wang, S., Gao, Y., Milius, R. A., Kula, N. S., Baldessarini, R. J., Zea-Ponce, Y., Baldwin, R. M., & Innis, R. B. (1994) · Journal of Medicinal Chemistry · doi:10.1021/jm00037a004 · Cited by 164
The Dopamine Transporter Is Absent in Parkinsonian Putamen and Reduced in the Caudate Nucleus
Niznik, H. B., Fogel, E. L., Fassos, F. F., & Seeman, P. M. (1991) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1991.tb02580.x · Cited by 154
Booij, J., Hemelaar, T. G., Speelman, J. D., de Bruin, K. M., Janssen, A. G. M., & van Royen, E. A. (1999) · PubMed · Cited by 120
Booij, J., Andringa, G., Rijks, L. J. M., Vermeulen, R. J., de Bruin, K. M., Boer, G. J., Janssen, A. G. M., & van Royen, E. A. (1997) · Synapse · doi:10.1002/(sici)1098-2396(199711)27:3<183::aid-syn4>3.0.co;2-9 · Cited by 105
Clinical impact of diagnostic SPET investigations with a dopamine re-uptake ligand
Løkkegaard, A., Werdelin, L., & Friberg, L. (2002) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-002-0938-7 · Cited by 54
Cited by
The diagnosis of Parkinson’s disease
Tolosa, E., Wenning, G., & Poewe, W. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(05)70285-4 · Cited by 902
Self-citationThe Parkinson's progression markers initiative (PPMI) – establishing a PD biomarker cohort
Marek, K., Chowdhury, S., Siderowf, A., Lasch, S., Coffey, C. S., Caspell‐Garcia, C., Simuni, T., Jennings, D., Tanner, C. M., Trojanowski, J. Q., et al. (2018) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.644 · Cited by 671
The role of radiotracer imaging in Parkinson disease
Ravina, B., Eidelberg, D., Ahlskog, J. E., Albin, R. L., Brooks, D. J., Carbon, M., Dhawan, V., Feigin, A., Fahn, S., Guttman, M., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000149403.14458.7f · Cited by 374
The role of DAT-SPECT in movement disorders
Kagi, G., Bhatia, K. P., & Tolosa, E. (2010) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2008.157370 · Cited by 311
Self-citationMorbelli, S., Esposito, G., Arbizu, J., Barthel, H., Boellaard, R., Bohnen, N. I., Brooks, D. J., Darcourt, J., Dickson, J. C., Douglas, D., et al. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-04817-8 · Cited by 273
Metadata
- Authors
- Catafau, A. M., & Tolosa, E.
- Venue
- Movement Disorders
- Publisher
- Wiley
- Published
- 2004-04-22
- Volume
- 19
- Issue
- 10
- Pages
- 1175-1182
- ISSN
- 0885-3185 (ISSN-L)
- 1531-8257
- OpenAlex
- W2017525257
- Cited by
- 290
- References
- 17
- FWCI
- 6.33
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.